Physician profile
Michael Grillo
NPI 1598147340
$6,668.73
in general payments reported to CMS, 2019-2025
36 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $1,085 · 2023: $1,648 · 2024: $1,398 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,237.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $631.41 | 2022-2025 | Watchman Flx, Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Medtronic, INC. | $620.48 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Micra |
| Pfizer INC. | $575.28 | 2023-2025 | |
| Novo Nordisk INC | $573.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $520.00 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $399.18 | 2022-2025 | Ensite, Mitraclip |
| Novartis Pharmaceuticals Corporation | $325.19 | 2023-2025 | |
| Esperion Therapeutics, INC. | $318.16 | 2021-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $257.63 | 2023-2025 | Optimizer, Optimizer |
| W. L. Gore & Associates, INC. | $199.39 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Alnylam Pharmaceuticals INC. | $197.78 | 2024-2025 | Onpattro, Amvuttra |
| Silk Road Medical, INC. | $179.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $179.72 | 2025 | Wainua, Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $169.28 | 2024 | Arcalyst |
| Atricure, INC. | $159.67 | 2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.